These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 28069100)

  • 21. In vitro efficacy of ceftriaxone/sulbactam against Escherichia coli isolates producing CTX-M-15 extended-spectrum beta-lactamase.
    Shahid M; Singhai M; Malik A; Shukla I; Khan HM; Shujatullah F; Tahira F
    J Antimicrob Chemother; 2007 Jul; 60(1):187-8. PubMed ID: 17491002
    [No Abstract]   [Full Text] [Related]  

  • 22. International dissemination of Escherichia coli strains with discrepant behaviour in phenotypic antimicrobial susceptibility tests.
    Creely D; Zambardi G; van Belkum A; Dunne WM; Peyret M; Gayral JP; Shortridge D; Shubert C
    Eur J Clin Microbiol Infect Dis; 2013 Aug; 32(8):997-1002. PubMed ID: 23397255
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Extended-spectrum β-lactamase producers reported as susceptible to piperacillin-tazobactam, cefepime, and cefuroxime in the era of lowered breakpoints and no confirmatory tests.
    Marchaim D; Sunkara B; Lephart PR; Gudur UM; Bhargava A; Mynatt RP; Zhao JJ; Bheemreddy S; Hayakawa K; Chopra T; Dhar S; Kaye KS
    Infect Control Hosp Epidemiol; 2012 Aug; 33(8):853-5. PubMed ID: 22759556
    [No Abstract]   [Full Text] [Related]  

  • 24. Irreproducible piperacillin/tazobactam minimum inhibitory concentrations in microdilution tests with Escherichia coli strains.
    Thomson KS; Black J; Moland ES; Reuben J; Wiles T; Brasso W
    Int J Antimicrob Agents; 2008 Jan; 31(1):83-5. PubMed ID: 17996426
    [No Abstract]   [Full Text] [Related]  

  • 25. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae.
    Thomson KS; Moland ES
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3548-54. PubMed ID: 11709338
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Population analysis of Escherichia coli isolates with discordant resistance levels by piperacillin-tazobactam broth microdilution and agar dilution testing.
    Shubert C; Slaughter J; Creely D; van Belkum A; Gayral JP; Dunne WM; Zambardi G; Shortridge D
    Antimicrob Agents Chemother; 2014; 58(3):1779-81. PubMed ID: 24342642
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk factors for piperacillin/tazobactam-resistant Escherichia coli in ICU patients: a clinical study.
    Mohammedi I; Ploin D; Duperret S; Chapuis F; Petit P
    Intensive Care Med; 2003 Jul; 29(7):1164-8. PubMed ID: 12774156
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of the increased use of piperacillin/tazobactam on the selection of antibiotic resistance among invasive Escherichia coli and Klebsiella pneumoniae isolates.
    Lee J; Oh CE; Choi EH; Lee HJ
    Int J Infect Dis; 2013 Aug; 17(8):e638-43. PubMed ID: 23523562
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum bactericidal activity of piperacillin/tazobactam against Staphylococcus aureus, piperacillin-susceptible and piperacillin-resistant Escherichia coli and Pseudomonas aeruginosa.
    Lemmen SW; Zolldann D; Klik S; Lütticken R; Kümmerer K; Häfner H
    Chemotherapy; 2004 Apr; 50(1):27-30. PubMed ID: 15084802
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incidence and impact on clinical outcome of infections with piperacillin/tazobactam resistant Escherichia coli in ICU: a retrospective study.
    Meybeck A; Ricard JD; Barnaud G; Eveillard M; Chevrel G; Mounier R; Dreyfuss D
    BMC Infect Dis; 2008 May; 8():67. PubMed ID: 18485230
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Susceptibility survey of piperacillin/tazobactam and some beta-lactam comparators in Italy.
    Stefani S; Bonfiglio G; Bianchi C; Zollo A; Nicoletti G
    Drugs Exp Clin Res; 1998; 24(2):105-13. PubMed ID: 9675551
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differences in the changes in resistance patterns to third- and fourth-generation cephalosporins and piperacillin/tazobactam among Klebsiella pneumoniae and Escherichia coli clinical isolates following a restriction policy in a Greek tertiary care hospital.
    Petrikkos G; Markogiannakis A; Papaparaskevas J; Daikos GL; Stefanakos G; Zissis NP; Avlamis A
    Int J Antimicrob Agents; 2007 Jan; 29(1):34-8. PubMed ID: 17189092
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Variable susceptibility to piperacillin/tazobactam amongst Klebsiella spp. with extended-spectrum beta-lactamases.
    Babini GS; Yuan M; Hall LM; Livermore DM
    J Antimicrob Chemother; 2003 Mar; 51(3):605-12. PubMed ID: 12615861
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Susceptibilities of ESBL-producing Enterobacteriaceae to ertapenem, meropenem and piperacillin-tazobactam with and without clavulanic acid.
    Raveh D; Yinnon AM; Broide E; Rudensky B
    Chemotherapy; 2007; 53(3):185-9. PubMed ID: 17347564
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro synergy studies based on tazobactam/piperacillin against clinical isolates of metallo-beta-lactamase-producing Pseudomonas aeruginosa.
    Fujimura S; Takane H; Nakano Y; Watanabe A
    J Antimicrob Chemother; 2009 Nov; 64(5):1115-6. PubMed ID: 19744981
    [No Abstract]   [Full Text] [Related]  

  • 36. [Usefulness of piperacillin/tazobactam resistance as a predictor of OXA-48 carbapenemase in Enterobacteriaceae].
    Grados M; Fernández S; Lara N; Alós JI
    Rev Esp Quimioter; 2017 Aug; 30(4):299-300. PubMed ID: 28541011
    [No Abstract]   [Full Text] [Related]  

  • 37. Antibacterial susceptibility of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
    Bishara J; Livne G; Ashkenazi S; Levy I; Pitlik S; Ofir O; Lev B; Samra Z
    Isr Med Assoc J; 2005 May; 7(5):298-301. PubMed ID: 15909461
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Accuracy of automated and manual systems for susceptibility testing of Pseudomonas aeruginosa to piperacillin and piperacillin-tazobactam.
    Gagliotti C; Sarti M; Sabia C; Gargiulo R; Rossolini GM; Carillo C; Cassani C; Cipolloni AP; Pedna F; Rossi MR; Incerti SS; Testa G; Venturelli C; Moro ML
    New Microbiol; 2011 Jan; 34(1):97-9. PubMed ID: 21344153
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
    Sader HS; Tosin I; Sejas L; Miranda E
    Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasmid-Mediated Colistin Resistance Gene mcr-1 in an Escherichia coli ST10 Bloodstream Isolate in the Sultanate of Oman.
    Mohsin J; Pál T; Petersen JE; Darwish D; Ghazawi A; Ashraf T; Sonnevend A
    Microb Drug Resist; 2018 Apr; 24(3):278-282. PubMed ID: 28799833
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.